SEC Company Response from Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142) (WHWK) — Feb 8, 2019
Whitehawk Therapeutics, Inc. (WHWK) (CIK 0001422142)
Date: Feb. 8, 2019 · CIK: 0001422142 · Accession: 0001193125-19-032418
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229087
Letter
Acceleration Request
Aerpio Pharmaceuticals, Inc.
9987 Carver Road
Cincinnati, OH
February 8, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Re: Aerpio Pharmaceuticals, Inc. (the “Company”)
Acceleration Request for Registration Statement on Form S-3
File No. 333-229087
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on February 12, 2019, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act.
Very truly yours,
Aerpio Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Aerpio Pharmaceuticals, Inc. 9987 Carver Road Cincinnati, OH 45242 February 8, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aerpio Pharmaceuticals, Inc. (the “Company”) Acceleration Request for Registration Statement on Form S-3 File No. 333-229087 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on February 12, 2019, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Danielle Lauzon at (617) 570-1955. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Securities Act. Very truly yours, Aerpio Pharmaceuticals, Inc. By: /s/ Stephen Hoffman Name: Title: Stephen Hoffman Chief Executive Officer cc: Goodwin Procter LLP